Waka A Udezi1
,
Rita O Akonoghrere2
For correspondence:- Waka Udezi Email: tonywaka@uniben.edu Tel: +2348037102111
Published: 31 December 2016
Citation: Udezi WA, Akonoghrere RO. Cost-effectiveness analysis of hepatitis B vaccination versus treatment. J Sci Pract Pharm 2016; 3(1):128-134 doi: 10.47227/jsppharm.v3i1.8
© 2016 The author(s).
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). This license requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only. .
Purpose: The aim of this study is to evaluate the cost-effectiveness of vaccination against hepatitis B compared to the treatment of those who became sick.
Methods: Data on time spent by each healthcare provider with a patient who has presented to the clinic to be vaccinated or treated for hepatitis B infection werecollected from the clinic. This time was converted to cost. The cost of drugs and vaccines with consumables were also collected. This data was used to construct a stochastic Monte Carlo model from the perspective of the clinic using a time frame of one year. The model reports the cost savings associated with policy change from treatment to vaccination. Sensitivity analysis was performed by varying data input by ±50%. P-values less than 0.05 were interpreted as significant.
Results: To adequately cover treatment cost NGN11,000.00 needs to be budgeted per person compared to about NGN3,400.00 needed to fund vaccination. This was found to be significant at p<0.05. Cost savings are in the range of NGN6,750 – 8,000 per person vaccinated while total cost savings to switch policy from treatment to vaccination will be NGN110-130milliom.
Conclusion: Vaccination of staff dependents and retirees is a more cost effective option in the management of hepatitis B compared to the current strategy of treatment of these individuals when they contract the disease. The cost savings which can be applied in other areas of need is about NGN120million
